Category: Uncategorized

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial

Study AER-01-002 is using a novel and precision imaging strategy to enroll

Read More

Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases

Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture

Read More
Scroll to Top